Current treatment results for relapsed/refractory acute myeloid leukaemia (AML) are typically poor. 1 Because some data suggest the value of increased anthracycline doses with intensive AML chemotherapies, 2, 3 we conducted a Phase I/II trial (ClinicalTrials.gov: NCT02044796) to test the efficacy of treatment with escalated doses of mitoxantrone in association with CLAG-M (or 'GCLAM'; cladribine/high-dose cytarabine/mitoxantrone/G-CSF) in adults ≥18 years with relapsed or refractory AML and other high-grade myeloid neoplasms (≥10% myeloblasts in blood and/or marrow).
Patients were eligible if they had a treatment-related mortality score of ≤6.9 (corresponding to a ≤6.9% probability of 4-week mortality 4 ). While this score was developed for adults with newly-diagnosed AML -and thus does not account for some variables relevant for relapsed/refractory disease 5 -we have previously used it in the relapsed/refractory disease setting. 6, 7 Patients were also required to have a left ventricular ejection fraction ≥45%, creatinine ≤2.0 mg/dL, and bilirubin ≤2.5 times the upper limit of normal, no uncontrolled infection, and expected survival of >1 year absent AML; for details, see Online Supplementary Information. In phase I, groups of 6-12 patients received 12, 14, 16, or 18 mg/m 2 (dose levels 1 -4) of intravenous (IV) mitoxantrone on days 1-3. Granulocyte colony-stimulating factor (G-CSF) was given subcutaneously (days 0-5), cladribine IV at 5 mg/m 2 (days 1-5), and cytarabine IV at 2 g/m 2 (days 1-5). The first 2 doses of G-CSF could be omitted if the total white blood cell count was >20,000/μL. Patients in phase II received mitoxantrone at the recommended phase II dose (RP2D) determined in phase I. A second, identical cycle of CLAG-M was given to patients who did not achieve complete remission (CR) or CR with incomplete hematologic recovery (CRi) in the first cycle. Patients in CR/CRi after one to two cycles could then receive up to 4 cycles of CLAG (mitoxantrone omitted). The protocol was approved by our Institutional Review Board, and patients gave written informed consent in accordance with the Declaration of Helsinki.
Between 2/2014 and 4/2017, we enrolled 60 patients (Table 1) . Among the 26 patients enrolled in phase I (Online Supplementary Table S1 ), one dose-limiting toxicity occurred at dose level 1 (12 mg/m 2 : nausea) and two at dose level 4 (18 mg/m 2 : encephalopathy and cardiogenic shock). Online Supplementary Table S2 summarizes phase I treatment outcomes, establishing CLAG-M with mitoxantrone at 16 mg/m 2 as the maximum tolerated dose/RP2D. This contrasts with our experience in a parallel cohort of adults with newly-diagnosed disease, in which all tested dose levels of mitoxantrone (including 18 mg/m2) were well tolerated. 8 Whether this difference reflects a greater vulnerability of patients with relapsed/refractory disease to higher doses of mitoxantrone or whether it is a chance finding due to the small patient numbers is unknown.
Forty patients (including 6 in phase I) with a median age of 63 [range: 33-77] years were treated at the RP2D (Table 1) . Table 2 summarizes best responses after 1-2 treatment cycles for the entire study population and for those treated at the RP2D. CR or CRi were achieved in 11 (28% [95% confidence interval: 15-44%]) and 13 (32% [19-49%]) patients, giving a CR/CRi rate of 60% (43-75%). Two of the 10 patients who received a second cycle of therapy had an improvement in response. Nine of the 11 CR (82%) and 10/13 of the CRi (77%) were negative for measurable residual disease (MRD neg ) as determined by flow cytometry. Among the others, 1 patient achieved a morphologic leukaemia-free state and 11 had resistant disease; two additional patients had normalized blood counts after CLAG-M but bone marrow examinations were not performed, limiting response assessment. Four-and 8-week mortality was 5% (2 deaths in aplasia). Infections and neutropenic fever were the most common non-hematologic grade 3-haematologica 2019; 104:e143 Table S4) . Among the CR patients, the median time to an absolute neutrophil count ≥1,000/μL was 29 (range: 27-67) days; the median time to a platelet count ≥100,000/μL was also 29 (range: 22-67) days. Fourteen of the 24 responders were taken off the protocol to undergo HCT, and 8 received alternative consolidation chemotherapies, many prior to transplantation. Twenty-two (55%) have received HCT to date, including 17/24 (71%) of the responders. Relapse, including emergence of minimal residual disease, occurred in 11 patients, while 3 patients died in remission after CR durations of 128, 167, and 379 days. With a median follow up among living patients of 20 months, the median OS and RFS for the RP2D group were 11 and 12 months ( Figures 1A and 1B) , with 1-year OS and RFS estimates of 44% and 47%.
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We next compared response rates and tolerability of CLAG-M in younger and older participants (Online Supplementary Table S5 ). CR rates in those <65 years vs. ≥65 years were 32% vs. 22%, MRD neg CR rates were 27% vs. 17%, and CR/CRi rates were 64% vs. 56%. Four-and 8-week mortality rates were low in both age groups (5%/5% and 6%/6% in younger vs. older patients). Rates of subsequent allogeneic HCT were similar (55% vs. 56%, younger vs. older). Median OS was 13 months for younger and 11 months for older patients; 1-year OS were 52% and 33%, respectively. Likewise, median RFS was 14 months for younger and 8 months for older patients (1-year RFS of 54% vs. 40%).
To determine whether escalation of mitoxantrone increases the anti-leukemia efficacy of CLAG-M, we took advantage of the fact that since 2012, a larger number of adults at our institution have received CLAG-M with mitoxantrone at 10 mg/m 2 (the dose reported originally by Polish investigators 9 ) for relapsed/refractory AML and other high-grade myeloid neoplasms. In our comparisons, we included 51 patients treated with CLAG-M with mitoxantrone at 16 mg/m 2 (40 on-study patients treated at the RP2D and 11 patients treated offprotocol) and 30 patients treated with CLAG-M with mitoxantrone at 10 mg/m 2 (all off-study), who all met the medical criteria for enrollment in our phase I/II study (i.e., treatment-related mortality (TRM) score ≤6.9, adequate organ function; see Online Supplementary Table S6 for patient characteristics). In multivariable analysis controlling for several prognostic factors, compared to patients treated with CLAG-M with mitoxantrone at 10 mg/m 2 , CLAG-M with mitoxantrone at 16 mg/m 2 was associated with significantly longer OS (hazard ratio [HR]=2.65 [1.44-4.89], P=0.0018; Figure 1C ) and nonsignificantly longer RFS (HR=1.51 [0.62-3.69], P=0.37), while remission rates were not different (Online Supplementary Table S7 ). Why the difference in outcomes was particularly noticeable for OS is unclear. The fact that a higher proportion of patients treated with mitoxantrone at 16 mg/m 2 underwent subsequent allogeneic HCT may play a role. However, an additional multivariable analysis in which allogeneic HCT was included as a time-dependent covariate showed a qualitatively similar result (for OS: HR=2.1, P=0.011). We also performed analyses in which we included all institutional patients treated with CLAG-M with mitoxantrone at either 16 mg/m 2 (n=55) or 10 mg/m 2 (n=43) regardless of TRM score and, controlling for TRM, obtained results qualitatively similar to those for patients with TRM score ≤6.9 (Online Supplementary Figure S1 and Online Supplementary  Table S8) .
Finally, we compared the outcomes of this study to those obtained with other high-dose cytarabine-containing salvage regimens used at our institution, namely GCLAC (G-CSF/clofarabine/cytarabine; n=56) and decitabine-primed MEC (d/MEC: decitabine/mitoxantrone/etoposide/cytarabine; n=36), which were given as part of two phase I/II studies (NCT00602225, 10, 11 
NCT01729845
7 ) or off-protocol, controlling for prognostic factors and restricting inclusion to patients with TRM scores of ≤6.9 (see Online Supplementary In summary, CLAG-M with mitoxantrone up to 16 mg/m 2 appears safe and relatively well tolerated in fit younger and older adults with relapsed/refractory AML and other high-grade myeloid neoplasms. Escalating the mitoxantrone dose may provide additional antileukemia efficacy over the dose conventionally used with CLAG-M, although non-randomized comparisons and small cohort sizes limit the conclusions we can draw from our analyses. Acknowledging the same limitations, our analyses suggest that outcomes with CLAG-M with escalated mitoxantrone doses may compare favourably to those obtained with another high-dose cytarabinebased salvage regimen, d/MEC, and may be at least as good as with GCLAC. Our study thus adds to the evidence supporting the use of CLAG-M for intensive AML re-induction therapy, perhaps particularly with higher mitoxantrone doses. 
